Swiss - Delayed Quote CHF

Roche Holding AG (RO.SW)

279.20

-0.60

(-0.21%)

As of 11:07:24 AM GMT+2. Market Open.

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

SOUTH SAN FRANCISCO, Calif., April 25, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary endpo

Business Wire 4 hours ago

RHHBF

RHHBY

RHHVF
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Zacks 17 hours ago

ROG.SW
-0.27%
LLY
Drugmakers brace for Trump tariffs, while weighing numerous other worries

(Reuters) -Major drugmakers were a standout on a tumultuous day of corporate earnings on Thursday, beating expectations even as they grapple with the threat of sector-specific tariffs, efforts to lower drug prices and federal layoffs that could undermine efforts to invest heavily in the U.S. in coming years. Bristol Myers Squibb, Merck & Co, Sanofi and Roche all exceeded quarterly earnings expectations on Thursday, and Bristol raised its profit forecast. Still, drugmakers are grappling with several factors that could cause upheaval, such as Trump administration efforts to shrink the federal workforce, including at the U.S. Food and Drug Administration, and probes into pharmaceutical imports that set the stage for levies on the sector.

Reuters 20 hours ago

ROG.SW
-0.27%
CELG-RT
Repertoire and Genentech to develop autoimmune disease therapies

Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones.

Pharmaceutical Technology 22 hours ago

ROG.SW
-0.27%
Roche introduces algorithm for ACS detection in individuals with chest pain

The algorithm utilises cardiac troponin testing and other diagnostic technologies.

Medical Device Network 22 hours ago

ROG.SW
-0.27%
Roche seeks US tariff relief in direct talks with Trump administration

(Reuters) -Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.S.-made drugs and diagnostics. He added that Roche was in touch with various levels of President Donald Trump's administration, arguing that a U.S. drive for all goods used in the country to be produced there would inflate manufacturing costs.

Reuters yesterday

ROG.SW
-0.27%
Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs.

The Wall Street Journal yesterday

RHHBF

RHHBY

RHHVF
Roche Q1 sales up 7% on drugs Phesgo, Vabysmo

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts. Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage.

Reuters yesterday

ROG.SW
-0.27%
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand for a broad range of our medicines; top growth drivers were Phesgo (breast cancer), Vabysmo (severe eye diseases), Xolair (allergies) and Hemlibra (haemophilia A).Diagnostics Division sales remained stable with high demand across products and regions offsetting the impact of the rec

GlobeNewswire yesterday

RHHBF

RHHBY

RHHVF
Roche looks to a Flagship startup in search of new immune drugs

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech division unearth T-cell targeting therapies for inflammatory diseases.

BioPharma Dive 2 days ago

ROG.SW
-0.27%
Switzerland flexes financial muscle ahead of tariff date in Washington

ZURICH (Reuters) -Top Swiss officials will this week test whether big commitments to the U.S. can help secure relief from import tariffs, after pharma giant Roche followed its cross-town rival Novartis in announcing major investments in the United States. Roche on Tuesday said it would invest $50 billion in the United States over the next five years, a day before Swiss Finance Minister Karin Keller-Sutter and Economy Minister Guy Parmelin lead a delegation on a three-day visit to Washington.

Reuters 2 days ago

ROG.SW
-0.27%
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device1 set to transform cardiac careThis novel algorithm offers a standardised assessment, helping emergency room doctors to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction)Cardiovascular disease causes a third of worldwide deaths2, with chest pain being the second highest reason for emergency department (ED)

GlobeNewswire 2 days ago

RHHBF

RHHBY

RHHVF
Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma

With threats of tariffs hanging over the pharmaceutical industry, Switzerland’s Roche announced on Tuesday that it will invest $50 billion in the United States over the next five years, expanding its existing facilities and building new manufacturing plants and research centers.

Quartz 2 days ago

ROG.SW
-0.27%
Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat

Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting their presence in the country since President Donald Trump came into office.

Investopedia 2 days ago

ROG.SW
-0.27%
Roche, answering tariff threat, pledges $50B to US drug production

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S., among them a gene therapy plant in Pennsylvania.

BioPharma Dive 2 days ago

ROG.SW
-0.27%
Pharma giant plots US weight-loss drug factory

Roche has pledged to build a giant weight-loss drug factory in the US.

The Telegraph 2 days ago

ROG.SW
-0.27%
Morning Bid:'Major loser' reporting for duty

It's no secret that U.S. President Donald Trump is not a fan of Federal Reserve Chair Jerome Powell, despite having appointed him to lead the U.S. central bank in 2018 during his first term in office. But in the face of a cratering stock market, the destruction of investor confidence in U.S. assets and the increasing likelihood of recession - all unleashed by the chaotic rollout of his tariff policies - Trump is demanding the Federal Reserve cut interest rates and for heads to roll, specifically, Powell's.

Reuters 2 days ago

ROG.SW
-0.27%
Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad. Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.

The Wall Street Journal 2 days ago

REGN

RHHBF

RHHBY
Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

Fortune 2 days ago

ROG.SW
-0.27%
Roche announces $50bn US investment in pharma and diagnostics

Once the new and expanded manufacturing capacities are operational, Roche aims to export more medicines from the US than it imports.

Pharmaceutical Technology 2 days ago

ROG.SW
-0.27%

Performance Overview

Return	RO.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+6.39%	-3.21%
1-Year	+20.36%	+8.31%
3-Year	-22.20%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RO.SW)

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

Drugmakers brace for Trump tariffs, while weighing numerous other worries

Repertoire and Genentech to develop autoimmune disease therapies

Roche introduces algorithm for ACS detection in individuals with chest pain

Roche seeks US tariff relief in direct talks with Trump administration

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push

Roche Q1 sales up 7% on drugs Phesgo, Vabysmo

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Roche looks to a Flagship startup in search of new immune drugs

Switzerland flexes financial muscle ahead of tariff date in Washington

Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

Roche says it will invest $50 billion in the U.S. as tariff fears hit pharma

Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat

Roche, answering tariff threat, pledges $50B to US drug production

Pharma giant plots US weight-loss drug factory

Morning Bid:'Major loser' reporting for duty

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Swiss drugmaker Roche leans into Trump tariff formula with $50 billion promise to invest in U.S.

Roche announces $50bn US investment in pharma and diagnostics

Performance Overview